Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hayat Pharmaceutical Industries Co EV-to-EBITDA?
Hayat Pharmaceutical Industries CoAMM:HPIC -1.25%47 EV-to-EBITDA is 6.28 as of Aug. 18, 2026, which is 21% above its 10-year median of 5.20. GuruFocus rates AMM:HPIC with a GF Score™ of 47/100. The stock has 8 warning signs investors should review. Among 734 Drug Manufacturers companies, Hayat Pharmaceutical Industries Co ranks better than 80.93% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hayat Pharmaceutical Industries Co's enterprise value is JOD26.40 Mil.
Hayat Pharmaceutical Industries Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was JOD4.20 Mil. Therefore, Hayat Pharmaceutical Industries Co's EV-to-EBITDA for today is 6.28.
AMM:HPIC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.03 Med: 5.2 Max: 10.02
Current: 6.28
During the past 13 years, the highest EV-to-EBITDA of Hayat Pharmaceutical Industries Co was 10.02. The lowest was 3.03. And the median was 5.20.
AMM:HPIC's EV-to-EBITDA is ranked better than 80.93% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs AMM:HPIC: 6.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hayat Pharmaceutical Industries Co (AMM:HPIC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hayat Pharmaceutical Industries Co's PE Ratio (TTM) for today is calculated as:
Hayat Pharmaceutical Industries Co's share price for today is JOD3.16.
Hayat Pharmaceutical Industries Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hayat Pharmaceutical Industries Co EV-to-EBITDA Chart
AMM:HPIC vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hayat Pharmaceutical Industries Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hayat Pharmaceutical Industries Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hayat Pharmaceutical Industries Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hayat Pharmaceutical Industries Co's EV-to-EBITDA falls into.
Hayat Pharmaceutical Industries Co's current Enterprise Value is JOD26.40 Mil.
Hayat Pharmaceutical Industries Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD4.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a EV-to-EBITDA of 6.28 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hayat Pharmaceutical Industries Co. This is 21% above median its historical median of 5.20. Over the past decade, Hayat Pharmaceutical Industries Co's EV-to-EBITDA has ranged from 3.03 to 10.02. According to the industry distribution chart, Hayat Pharmaceutical Industries Co ranks #140 out of 734 companies in the Drug Manufacturers industry, placing it in the top 19.1%.
Is Hayat Pharmaceutical Industries Co's EV-to-EBITDA too high?
Hayat Pharmaceutical Industries Co's current EV-to-EBITDA of 6.28 is 21% above median its 10-year median of 5.20. Over the past 10 years, this metric has ranged from a low of 3.03 to a high of 10.02. The Drug Manufacturers industry median EV-to-EBITDA is 13.44. Hayat Pharmaceutical Industries Co's value of 6.28 is 53.3% below this industry median. Based on the distribution chart, Hayat Pharmaceutical Industries Co ranks #140 out of 734 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hayat Pharmaceutical Industries Co ranks #140 out of 734 companies for EV-to-EBITDA. This places Hayat Pharmaceutical Industries Co in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.44. Hayat Pharmaceutical Industries Co's value of 6.28 is 53.3% below this benchmark. Historically, Hayat Pharmaceutical Industries Co's own EV-to-EBITDA has ranged from 3.03 to 10.02 over the past decade. While the company's 10-year median is 5.20 vs. the industry median of 13.44, Hayat Pharmaceutical Industries Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hayat Pharmaceutical Industries Co's current EV-to-EBITDA of 6.28 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hayat Pharmaceutical Industries Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hayat Pharmaceutical Industries Co's current EV-to-EBITDA is 6.28, which is 21% above median its own 10-year median of 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a current EV-to-EBITDA of 6.28. The current EV-to-EBITDA is 6.28, which is 21% above median its 10-year median of 5.20 and 53.3% below the Drug Manufacturers industry median of 13.44. Hayat Pharmaceutical Industries Co's overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current EV-to-EBITDA is 6.28 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
47GF Score
Get the complete analysis for AMM:HPIC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:HPIC has been successfully added to your 
